Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
This article was originally published in The Pink Sheet Daily
Executive Summary
Now in confidential talks with Sanofi and other buyout suitors, Medivation hopes to increase offers on the basis of its PARP inhibitor's dual-mechanism promise.
You may also be interested in...
Clovis Transitions To Commercial Stage On Rubraca Approval
FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.
With Medivation, Pfizer Sees A Chance For More Combinations
Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.